BackAkebia Therapeutics Overview

Akebia Therapeutics Receivables

Akebia Therapeutics's receivables is $54M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$53.51M
↓ 26.51% YoYΔ $-19.30M vs prior year quarter

Peer trimmed avg / median

Loading

Akebia Therapeutics Receivables History

Loading

Akebia Therapeutics vs. peers: Receivables Comparison

Loading

Akebia Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Akebia Therapeutics (AKBA) FAQ

As of the most recent data (June 2026), AKBA shows a receivables of $54M. That compares with $73M in the prior-year period — down 26.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKBA's receivables is now $54M (was $73M) — a 26.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akebia Therapeutics is outperforming or lagging.

Tracking AKBA's receivables over time shows whether Akebia Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $54M That compares with $73M in the prior-year period — down 26.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Akebia Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $54M) with ownership activity and broader fundamentals.

Akebia Therapeutics's receivables is $54M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.